SCHEMBL174015

SCHEMBL174015

O=C(OO)C1=CC=CC(=O)C1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30932236 0.80
SCHEMBL4243463 0.79
SCHEMBL8520246 0.76
SCHEMBL16099595 0.73
SCHEMBL27478170 0.67
SCHEMBL8674401 0.65
SCHEMBL28515648 0.63 ALDH1A1 (0.33)
SCHEMBL30828319 0.61 HSD17B10 (0.34)
SCHEMBL5798327 0.60
SCHEMBL28299327 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126862-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. (US) 2023-02-08 EP claimed
WO-2021202688-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. (US) 2021-10-07 WO claimed
EP-3472137-A1 PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES ScinoPharm Taiwan, Ltd. (TW) 2019-04-24 EP claimed
EP-3433230-A1 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2019-01-30 EP claimed
WO-2017222474-A1 PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES SCINOPHARM TAIWAN, LTD. (TW) 2017-12-28 WO claimed
WO-2017165878-A1 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-09-28 WO claimed
EP-2912027-A1 NOVEL EPOXIDE COMPOUNDS: 1,3-DIOXIRANYLCYCLOPENTANE DERIVATIVES Dow Global Technologies LLC (US) 2015-09-02 EP claimed
WO-2014152737-A1 SELECTIVE MODIFICATION OF ORGANIC COMPOUNDS IN THE PRESENCE OF AMINES AND/OR SULFIDES HEPATOCHEM (US) 2014-09-25 WO claimed
EP-2744771-A1 C-HALOGEN BOND FORMATION The Trustees of Princeton University (US) 2014-06-25 EP claimed
WO-2014066717-A1 NOVEL EPOXIDE COMPOUNDS: 1,3-DIOXIRANYLCYCLOPENTANE DERIVATIVES DOW GLOBAL TECHNOLOGIES LLC (US) 2014-05-01 WO claimed
WO-2013028639-A1 C-HALOGEN BOND FORMATION THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2013-02-28 WO claimed
EP-4380560-A1 LPAR1 ANTAGONISTS AND USES THEREOF Contineum Therapeutics, Inc. (US) 2024-06-12 EP disclosed
WO-2024112865-A1 METHOD OF SYNTHESIZING 4'-PHOSPHATE ANALOG NUCLEOTIDE PHOSPHORAMIDITE ELI LILLY AND COMPANY (US) 2024-05-30 WO disclosed
EP-4362978-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2024-05-08 EP disclosed
WO-2024064024-A1 ((4-OXO-3,4-DIHYDROQUINAZOLIN-8-YL)METHYL)AMINE DERIVATIVES AS P13K INHIBITORS FOR THE TREATMENT OF CANCER ONKURE, INC. (US) 2024-03-28 WO disclosed
EP-1007515-A1 ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS Abbott Laboratories (US) 2000-06-14 EP disclosed
WO-1999026941-A1 SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS AXYS PHARMACEUTICALS, INC. (US) 1999-06-03 WO disclosed
WO-1999010331-A1 ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS ABBOTT LABORATORIES (US) 1999-03-04 WO disclosed
WO-1998027080-A1 CHROMONES USEFUL AS FUNGICIDES AGREVO UK LIMITED (GB) 1998-06-25 WO disclosed
EP-0836602-A1 FUNGICIDAL PYRIMIDINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-04-22 EP disclosed